ArticleInternational journal of women's health2026
Genomic Profile of Interleukin-6 Secreting Ovarian Cancer: Validation of Future Biomarkers and Target of Therapy.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammation is one of the main events in ovarian cancer pathogenesis. Ovarian cancer secreting interleukin-6 (IL-6) as a pro-inflammatory cytokine can have altered genetic profiles that contribute to the progression of the disease. The lack of integrative studies combining quantitative IL-6 measurement with genomic profiling in ovarian cancer has not been further assessed. Therefore, this study aimed to explore genomic profile of ovarian cancer using the most current sequencing method to identify fundamental alterations in the pathobiology. Genomic profiles further may provide candidate biomarkers for future validation. Methods: A total of 45 subjects were recruited and received surgery for indications of an ovarian tumor. Among these subjects, 18 were diagnosed as malignant disease, 19 were considered benign and 8 as borderline ovarian cancer. IL-6 level was measured from both serum and intratumoral with ELISA. Ovarian cancer with a high secretion level of IL-6 received deep whole-genome sequencing performed with ONT. Results: The results showed that the secretion level of IL-6 was consistent in serum and intratumoral fluid. In addition, patients with malignancy showed significant secretion of IL-6 compared to benign disease (p = 0.027), according to systemic inflammation markers (NLR, PLR, and SII). Based on sequencing, IL-6-secreting ovarian cancer showed alteration of genes for MTRF1, IL-10, IL-6, APC, PAX8, PTGS2, and PACERR. Conclusion: Ovarian malignancy has a significant secretion of pro-inflammatory cytokines. Additionally, the inflammatory condition contributes to the disruption of genetic landscapes in the ovarian cancer pathogenesis. As an exploratory cross-sectional analysis, these findings identify potential associations and candidate genomic features involved in ovarian cancer pathogenesis, diagnosis and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.